No 03 2020

Milla Koistinaho and her colleagues at Innovestor’s life science fund focus their investments on Nordic and Baltic-based startups that work on either transformative therapeutic opportunities addressing significant unmet medical needs, or digital solutions to inefficiencies in healthcare and providing better care and treatment.

AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group Limited.

The collaboration combines Salipro Biotech's expertise and its Salipro platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug discovery programs for the generation of small molecule drugs.

Despite international turbulence and news of life sciences and research funding disruptions in the U.S., investment in innovative life sciences projects continues, according to Mala Valroy, an investment manager with Industrifonden, one of Sweden’s largest evergreen venture capital (VC) funds. 


The board of SyntheticMR has appointed Lena Åredal as the new CEO.

The two companies will advance the development of two blood-brain barrier (BBB)-crossing recombinant enzyme replacement therapies (ERT) for lysosomal storage disorders (LSD), including alpha-mannosidosis (aMann) and Krabbe disease (KD), ultra-rare diseases that affect the central nervous system.

25 new researchers from all over the world will hopefully arrive in Lund this autumn.